Jove
Visualize
Contact Us

Related Experiment Videos

Antibacterial drug discovery and structure-based design.

John J Barker1

  • 1Evotec UK, 111 Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK. john.barker@evotec.com

Drug Discovery Today
|April 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural insights into selective small molecule activation of PKG1α.

Communications biology·2023
Same author

Development of a robust crystallization platform for immune receptor TREM2 using a crystallization chaperone strategy.

Protein expression and purification·2020
Same author

High-Throughput Production of Proteins in E. coli for Structural Studies.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo.

Journal of medicinal chemistry·2015
Same author

Structural and biochemical studies of a moderately thermophilic exonuclease I from Methylocaldum szegediense.

PloS one·2015
Same author

Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).

Bioorganic & medicinal chemistry letters·2014
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Bacterial resistance is a growing threat, with few new antibiotics in development. Structure-based design offers a way to accelerate the discovery of novel antibacterial drugs by targeting newly identified bacterial structures.

Area of Science:

  • Microbiology and Infectious Diseases
  • Drug Discovery and Development
  • Structural Biology

Background:

  • Antimicrobial resistance (AMR) is a significant global health threat, exacerbated by a declining pipeline of novel antibacterial agents.
  • Pharmaceutical industry focus on other therapeutic areas has led to a shortfall in antibiotic research and development.
  • Emerging bacterial resistance necessitates urgent innovation in antibacterial discovery.

Purpose of the Study:

  • To highlight the critical need for novel antibacterial discovery.
  • To emphasize the potential of structure-based design in addressing the antibiotic pipeline shortfall.
  • To advocate for the exploitation of structure-genomics data in antibacterial drug development.

Main Methods:

  • Leveraging structure-genomics initiatives to identify novel bacterial targets.

Related Experiment Videos

  • Employing structure-based drug design principles and computational tools.
  • Analyzing newly elucidated bacterial structures for potential drug interactions.

    • Main Results:

    • Structure-genomics has provided a substantial number of potential targets for antibacterial intervention.
    • Structure-based design methodologies are well-suited to exploit these newly identified targets.
    • Accelerated antibacterial discovery is achievable through the strategic application of these tools.

    Conclusions:

    • The identified bacterial targets from structure-genomics represent a valuable resource for drug discovery.
    • Structure-based design is a key strategy to overcome the current challenges in developing new antibiotics.
    • Exploiting these targets is crucial to replenish the dwindling pipeline of antibacterial therapeutics and combat resistance.